Skip to main content

Table 3 Clinical course during the observation

From: Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Parameters

Baseline

Change to 3 months follow-up

Change to 6 months follow-up

Mean ± standard deviation

n

Mean ± standard deviation

n

Mean ± standard deviation

n

6-min walking distance, meters

267.7 ± 110.1

6

− 8.8 ± 62.4

6

4.7 ± 41.4

6

N-terminal pro brain natriuretic peptide, pg/l

4871.3 ± 6684.7

8

− 453.4 ± 5268.5

8

− 1159.6 ± 3446.2

8

SaO2 [%]

93.3 ± 2.4

12

− 0.5 ± 4.1

12

1.3 ± 3.1

11

Quality of Life (SF-36)

 Physical component score

34.4 ± 16.7

8

8.0 ± 17.0

8

6.6 ± 13.8

10

 Mental component score

45.1 ± 25.1

8

2.5 ± 29.8

8

1.0 ± 15.5

10

 Physical function

19.4 ± 15.5

8

5.0 ± 11.0

8

4.0 ± 13.3

10

 Physical role performance

12.5 ± 35.4

8

25. ± 37.8

8

20 ± 36.9

10

 Bodily pain

65.1 ± 18.9

8

9.3 ± 25.4

8

8.5 ± 16.1

10

 General health

40.1 ± 17.4

8

− 2.3 ± 26.3

8

− 1.3 ± 17.6

10

 Vitality

35.0 ± 24.9

8

3.8 ± 24.9

8

2.0 ± 16.0

10

 Sovial functioning

51.6 ± 33.1

8

4.8 ± 37.0

8

− 1.3 ± 22.4

10

 Emotional role performance

50.0 ± 53.5

8

0.0 ± 71.3

8

0.0 ± 47.1

10

 Mental health

49.0 ± 20.3

8

6.5 ± 24.3

8

3.5 ± 19.9

10

Lung function

 FVC (L)

2.4 ± 0.6

7

0.2 ± 0.3

7

0.01 ± 0.4

7

 FVC /FEV1[%]

73.3 ± 6.0

7

0.6 ± 4.2

7

2.7 ± 5.1

7

 FEV1 [L]

1.9 ± 0.4

7

0.1 ± 0.1

7

0.04 ± 0.3

7

 PEF [L/sec]

4.4 ± 1.5

7

0.2 ± 0.5

7

0.3 ± 0.6

7

 DLCO [%]

50.1 ± 28.2

4

7.5 ± 8.3

4

0.13 ± 12.4

6

 TLC [L]

5.2 ± 0.9

7

− 0.4 ± 0.9

7

− 0.2 ± 0.8

7

 Residual volume [L]

2.7 ± 1.3

7

− 0.4 ± 0.9

7

0.1 ± 0.9

7

Echocardiography at rest

 sPAP [mmHg]

82.0 ± 15.7

10

− 9.2 ± 19.9

10

− 9.0 ± 25.8

10

 RA area [cm2]

23.2 ± 5.8

11

0.8 ± 6.6

11

− 0.4 ± 6.3

10

 RV area [cm2]

27.5 ± 6.2

11

− 1.5 ± 5.9

11

2.4 ± 5.8

10

 TAPSE [cm]

1.98 ± 0.61

11

− 0.07 ± 0.35

11

0.09 ± 0.48

10

 Tei-index

0.86 ± 0.32

8

− 0.15 ± 0.19

8

− 0.04 ± 0.23

7

Right heart catherization

 mPAP [mmHg]

58.3 ± 7.6

3

  

− 6.7 ± 11.5

3

 sPAP [mmHg]

98.7 ± 11.8

3

  

− 11.7 ± 20.2

3

 dPAP [mmHg]

36.6 ± 6.1

3

  

− 3.3 ± 5.8

3

 PVR [dyn × s × cm−5]

8.2 ± 3.9

3

  

− 0.6 ± 1.1

3

 mRAP [mmHg]

10.3 ± 4.6

3

  

− 4.0 ± 6.9

3

 PAWP [mmHg]

10.3 ± 3.2

3

  

− 2.7 ± 4.6

3

 Cardiac output [l/min]

6.4 ± 1.8

3

  

0.3 ± 0.5

3

 Cardiac index [l × min × m−2]

2.8 ± 0.5

3

  

0.03 ± 0.23

3

  1. DLCO: diffusing capacity of carbon monoxide, dPAP: diastolic pulmonary arterial pressure, FVC: forced vital capacity, FEV1: forced expiratory volume in the first second, mPAP: mean pulmonary arterial pressure, mRAP: mean right atrial pressure, NT-proBNP: n-terminal pro brain natriuretic peptide, PAWP: pulmonary arterial wedge pressure, PEF: peak expiratory flow, PVR: pulmonary vascular resistance, RA: right atrial, RV: right ventricular, SaO2: oxygen saturation, SF-36: short form health survey 36, sPAP: systolic pulmonary arterial pressure, TAPSE: tricuspid annular plane systolic excursion, TLC: total lung capacity, WHO: World Health Organization